Online inquiry

IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8453MR)

This product GTTS-WQ8453MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets TLR3 Agonist. The antibody can be applied in Cervical dysplasia vaccine research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Mycobacterium tuberculosis variant bovis; Alphapapillomavirus 9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8453MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7688MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ13138MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ15114MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ4766MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ4751MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BPS-804
GTTS-WQ6070MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ11248MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ15562MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW